Emerging Atopic Dermatitis Treatments:
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
Atopic Dermatitis
Hypotheses of Atopic Dermatitis
Atopic Dermatitis and Immune Dysfunction
Skin Barrier Dysfunction
Immune System Dysfunction
Crisaborole Topical PDE4 Inhibitor
Crisaborole Topical PDE4 Inhibitor (cont)
Patient Education
Apremilast Oral PDE4 Inhibitor
Dupilumab IL-4 Receptor α Inhibitor
Dupilumab IL-4/IL-13 Inhibitor
Dupilumab IL-4/IL-13 Inhibitor
Dupilumab Pediatric Studies
IL-13 Inhibitors Lebrikizumab and Tralokinumab
Lebrikizumab and Tralokinumab
Nemolizumab IL-31 Receptor Inhibitor
Nemolizumab
JAK Inhibitors Baricitinib and Tofacitinib
JAK Inhibitors
Patient-Centric Management of AD
The AD Tool Kit
Concluding Remarks
Abbreviations